Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml;  ;  ;   - solution for injection - 600mg/4ml - active: clindamycin phosphate 178.22 mg/ml equivalent to clindamycin base 150 mg/ml       excipient: benzyl alcohol disodium edetate dihydrate hydrochloric acid sodium hydroxide water for injection - clindamycin phosphate has been shown to be effective in the treatment of the following infections when caused by susceptible anaerobic bacteria or susceptible strains of gram positive bacteria such as streptococci, staphylococci and pneumococci: 1. upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 100mg;   - capsule - 100 mg - active: fluconazole 100mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 150mg;   - capsule - 150 mg - active: fluconazole 150mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 200mg;   - capsule - 200 mg - active: fluconazole 200mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 50mg;   - capsule - 50 mg - active: fluconazole 50mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 10 mg/ml;  ;   - powder for oral suspension - 10 mg/ml - active: fluconazole 10 mg/ml     excipient: citric acid colloidal silicon dioxide orange flavour 57458 ap05514 sodium benzoate sodium citrate dihydrate sucrose titanium dioxide xanthan gum - cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. diflucan can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 40 mg/ml;  ;   - powder for oral suspension - 40 mg/ml - active: fluconazole 40 mg/ml     excipient: annatto citric acid colloidal silicon dioxide sodium benzoate sodium citrate dihydrate sucrose titanium dioxide xanthan gum - cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. diflucan can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 2 mg/ml;   - solution for infusion - 100mg/50ml - active: fluconazole 2 mg/ml   excipient: sodium chloride water for injection - latest regulatory activity

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - fluconazole 150mg;   - capsule - 150 mg - active: fluconazole 150mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch patent blue v tekprint black sw-9008 titanium dioxide - vaginal candidiasis.

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - axitinib 1mg;   - film coated tablet - 1 mg - active: axitinib 1mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry red 32k15441 - treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.